A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes

Abstract Background Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed...

Descrizione completa

Dettagli Bibliografici

Autori principali:	A. G. Vakrakou, D. Tzanetakos, S. Valsami, E. Grigoriou, K. Psarra, J. Tzartos, M. Anagnostouli, E. Andreadou, M. E. Evangelopoulos, G. Koutsis, C. Chrysovitsanou, E. Gialafos, A. Dimitrakopoulos, L. Stefanis, C. Kilidireas
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2018-10-01
Serie:	BMC Neurology
Soggetti:	Multiple sclerosis Alemtuzumab Neutropenia Large granular cells
Accesso online:	http://link.springer.com/article/10.1186/s12883-018-1183-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!